Navigation
On Topic
Complete Directory
About Us
Add-site
Link to Us
MerchantStore
Shopping

Google


Advertisement
77 Health - AIDS Resources
11.5 percent HIV/AIDS prevalence in Mozambique: report
Almost 12 percent of the Mozambican population is infected with HIV/AIDS, a government survey released on Monday said.
View SourceJuly 5, 2010Provides Information
12 myths about HIV/AIDS and people who use drugs
In a Comment which forms part of the Series in Lancet, 12 myths about HIV/AIDS are debunked.
View SourceJuly 20, 2010Provides Information
A
A Revolution in Counting CD4 Cells in HIV+ Patients Set to Enter Trials
CD4 cells, one of the white blood cell types that HIV attacks, serve as a sort of bellwether for the progression of an HIV infection. A patient's CD4 cell values help a physician determine their risk for specific opportunistic infections, evaluate if the patient should be placed on anti-retrovirals, and help indiciate if the treatment provided is effective. In other words, knowing an HIV positive patient's CD4 cell values is more or less critical to efficient and proper treatment.
View SourceJune 29, 2010Provides Information
Adding nucleic acid testing to HIV screening may help identify more people with HIV
Community-based HIV testing programs generally use only HIV antibody testing, but nucleic acid testing (NAT) can detect the presence of HIV earlier. Researchers at the University of California, San Diego School of Medicine studied more than 3,000 patients who sought HIV testing in community-based clinics in or near San Diego to examine the yield of testing with a rapid test plus NAT and to see whether patients would be willing to access their results by phone or computer.
View SourceJune 14, 2010Provides Information
Administration plans to release new HIV/AIDS strategy this week
Federal officials plan to announce Tuesday a national strategy designed to ramp up and better coordinate the government's attack on the country's HIV/AIDS epidemic, an effort to deliver on a Barack Obama campaign promise delayed by the health care overhaul debate and other issues.
View SourceJuly 12, 2010Provides Information
Africa's grandmothers debate HIV/Aids
African grandmothers have gathered in Swaziland to discuss the impact of HIV/Aids on their lives.
View SourceMay 6, 2010Provides Information
AIDS 2010 calls for extension of human rights protections as central tenet of global response to AIDS
AIDS 2010 delegates, speakers and organizers call for an end to the passive neglect and active denial that thwart access to life-saving health services, information and tools that fuel the HIV epidemic
View SourceJuly 23, 2010Provides Information
AIDS drugs given to pregnant women block 99 percent of HIV transmission to breastfed babies
An international clinical trial led by researchers at the Harvard School of Public Health (HSPH) has found that AIDS-fighting antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana, Africa, prevented 99% of the mothers from transmitting the human immunodeficiency virus (HIV) to their infants.
View SourceJune 16, 2010Provides Information
AIDS Gel With Gilead Drug Protects Women in Study
Researchers are reporting a breakthrough against AIDS. A vaginal gel containing an AIDS drug cut in half a woman's chances of getting HIV from an infected partner.
View SourceJuly 19, 2010Provides Information
AIDS Patients Cite Stigma, Depression
Many HIV/AIDS Patients Haven’t Disclosed Their Health Status to Partners, Survey Finds
View SourceJuly 22, 2010Provides Information
AIDS spreading in Eastern Europe and Central Asia
Experts and activists are warning that AIDS in Eastern Europe and Central Asia is on the rise even as a global conference reports progress on other fronts.
View SourceJuly 20, 2010Provides Information
AIDS Virus Changes in Semen Make It Different Than in Blood
Worldwide much of the transmission of HIV-1 is through sexual contact, men being the transmitting partner in a majority of cases. The new findings are significant because the nature of the virus in the male genital tract is of central importance to understanding the transmission process and the selective pressures that may impact the transmitted virus. Ultimately it is the transmitted virus that must be blocked by a vaccine or microbicide.
View SourceAugust 20, 2010Provides Information
Annie Lennox trying to get world to see changing face of AIDS
Singer and activist Annie Lennox wants the world to know that the HIV virus and the debilitating condition it causes, AIDS, are the leading killers of women of reproductive age in the world.
View SourceMarch 13, 2010Provides Information
Anti-HIV drugs slash risk of virus transmission by 92 percent
People with HIV reduced the risk of handing on the AIDS virus by an astonishing 92 percent while they were taking antiretroviral drugs, according to a trial reported on Thursday.
View SourceMay 26, 2010Provides Information
Antibodies found that provide protection against AIDS
Discovery could lead to development of a vaccine against the deadly virus
View SourceJuly 8, 2010Provides Information
Antiviral Gene Helps Suppress Jumping of AIDS Viruses Between Host Species
The human AIDS viruses (HIV-1 and HIV-2) originated as viruses of apes and monkeys, respectively, yet little is known about whether or how these invaders adapted to the new genetic "environment" encountered in humans. One group of host genes, collectively known as restriction factors, is thought to influence the ability of such viruses to move between different primate species. A study conducted by Andrea Kirmaier and Welkin Johnson of Harvard Medical School, together with Dr. Vanessa Hirsch of the National Institutes of Health, provides direct evidence in apes and monkeys of a restriction factor gene called TRIM5 acting as a genetic barrier to cross-species transmission of a primate immunodeficiency virus related to HIV-2.
View SourceAugust 25, 2010Provides Information
B
Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Hubei Tianyuan Chemical Co., Ltd. of Yangxin Nacheng Chemical Industry Zone, located in Hubei Province, China. This expected acquisition is the third of several planned acquisitions targeted at a share price in excess of US $1.50 for Biomagnetics Diagnostics' common shares. Biomagnetics plans to rapidly transition the trading of its shares to the OTCBB.
View SourceAugust 27, 2010Provides Information
C
Cellular and molecular events that restrict HIV transmission identified
Researchers from Boston University School of Medicine (BUSM) have identified two molecules that when activated by drugs, can inhibit a number of specific aspects of HIV transmission. These findings, published July 1 in the open-access journal PLoS Pathogens, may lead to therapies that target mucosal HIV transmission.
View SourceJuly 1, 2010Provides Information
Childhood sexual abuse and social shaming linked to health issues later
Gay and bisexual men enrolled in a long-term study of HIV who reported sexual abuse and social shaming in childhood experience psychosocial health problems later in life that could put them at greater risk for HIV, report University of Pittsburgh Graduate School of Public Health researchers at the XVIII International AIDS Conference.
View SourceJuly 21, 2010Provides Information
Consortium seeks best treatment for HIV-positive cancer patients
Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
View SourceJune 7, 2010Provides Information
D
Distributed Computing Helps in AIDS Fight
The Scripps Research Institute has just published a study that identifies the existence of new binding sites on HIV protease. Two compounds were found that attach themselves to the new spots on the protease, a feat that was possible thanks to people volunteering their idle computer cycles to FightAIDS@Home.
View SourceMarch 3, 2010Provides Information
F
Future HIV vaccines: If we build it, will they come?
On the eve of the world's biggest AIDS conference this month in Austria, a new research review shows many people wouldn't get inoculated against HIV even if a vaccine was developed.
View SourceJuly 14, 2010Provides Information
G
Gene Change Raises Odds of Mother-to-Child HIV Transmission
A correlation has been discovered between specific variants of the gene that codes for a key immune system protein, TLR9, and the risk of mother-to-child, or vertical, transmission of HIV.
View SourceMay 26, 2010Provides Information
Genetic Immunity Develops Nanomedicine Therapeutic Vaccine for HIV/AIDS
Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company’s innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.
View SourceMay 13, 2010Provides Information
Genetic Immunity Releases Phase II Study Result of DermaVir Nanomedicine
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria.
View SourceJuly 19, 2010Provides Information
Genetic Immunity to Present on DermaVir Nanomedicine Therapeutic Vaccine for HIV/AIDS at DNA Vaccines 2010, LA
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS.
View SourceMarch 3, 2010Provides Information
German singer Nadja Benaissa apologises at HIV trial
A singer from German girl band No Angels has admitted to having unprotected sex with several partners without warning them she was HIV-positive.
View SourceAugust 16, 2010Provides Information
Gilead AIDS drug safe for HIV prevention in study
Gilead's HIV drug tenofovir is safe to be given to men at high risk of contracting the virus as a preventative measure, scientists said on Friday, but further trials are needed to test its efficacy.
View SourceJuly 23, 2010Provides Information
Global Fund freezes Zambia aid over corruption concern
More than $300m of health funding to Zambia's goverment is being suspended by the Global Fund to fight Aids, Tuberculosis and Malaria.
View SourceJune 16, 2010Provides Information
Global Fund seeks cash to fight AIDS, TB, malaria
A global group funding the battle against AIDS, malaria and tuberculosis in impoverished nations worldwide is urging donors to keep paying for the fight even as the economic crisis forces budget cuts.
View SourceMarch 24, 2010Provides Information
H
Half of HIV-exposed babies in parts of Africa not receiving available HIV prevention
In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.
View SourceJuly 18, 2010Provides Information
HIV-infected drug users at greater risk of viral hepatitis, tuberculosis, bacterial infections and mental illness
HIV-infected drug users have increased age-matched morbidity and mortality compared with HIV-infected people who do not use drugs. This includes an increased risk of viral hepatitis, tuberculosis (TB), bacterial infections, and mental illness. In a new paper in The Lancet Series on HIV in people who use drugs, Professor Frederick L Altice, Yale University, New Haven, CT, USA, and colleagues show that there are evidence based treatments for both HIV and these co-morbidities, and that antiretroviral treatment (ART) for HIV can improve not only the course of HIV infection but also these other conditions.
View SourceJuly 20, 2010Provides Information
HIV-Like Virus Found in Illegally Imported Meat
Researchers testing bushmeat smuggled into the U.S. have found strains of a virus in the same family as HIV, according to preliminary findings to be released Wednesday.
View SourceApril 14, 2010Provides Information
HIV patients with lymphoma given new hope
The Human Immunodeficiency Virus (HIV) is widely treated using highly active antiretroviral therapy (HAART), which patients must continue throughout their lives. Now a new study suggests the patients’ own stem cells could be genetically modified and then transplanted back into their bodies to give them a single administration therapy, given once and lasting for life. This could avoid the costs and the toxic side effects of the traditional HAART.
View SourceJune 18, 2010Provides Information
HIV positive acrobat may have affected hundreds nationwide
HIV infected acrobat, 32 year old Godfrey Zaburoni allegedly infected hundreds of women all over Australia and a special task force will help track down all of these women.
View SourceMay 27, 2010Provides Information
HIV prevention strategy key to curbing epidemic and cutting long-term treatment costs
Increasing highly active antiretroviral therapy (HAART) treatment for people with HIV/AIDS will provide significant cost savings over a relatively short period of time, according to a formal economic analysis led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at Providence Health Care and the University of British Columbia (UBC).
View SourceJuly 7, 2010Provides Information
HIV vaccines may induce HIV antibodies in trial participants, can cause false-positive test result
During trials of preventive HIV vaccines, trial participants may develop HIV-related antibody responses that could lead to a positive HIV test by routine antibody detection methods (called vaccine-induced seropositivity/reactivity [VISP]), and the potential for false-positive test results and an incorrect HIV diagnosis, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.
View SourceJuly 18, 2010Provides Information
HIV virus hides in the brain
Studies of the spinal fluid of patients given anti-HIV drugs have resulted in new findings suggesting that the brain can act as a hiding place for the HIV virus. Around 10% of patients showed traces of the virus in their spinal fluid but not in their blood -- a larger proportion than previously realised, reveals a thesis from the University of Gothenburg, Sweden.
View SourceAugust 23, 2010Provides Information
I
Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy
The largest study to date to examine methods to prevent HIV infection among breastfeeding infants concludes that giving antiretroviral drugs to HIV-infected breastfeeding mothers in sub-Saharan Africa or giving an HIV-fighting syrup to their babies are both effective.
View SourceJune 17, 2010Provides Information
M
Many With HIV Start Care Too Late
Despite growing evidence that the earlier people are diagnosed with HIV and get access to care, the better their clinical outcomes, many HIV-infected people in the United States and Canada are not receiving the care they need early enough. A study of nearly 45,000 patients in both countries highlighting this trend appears in the June 1, 2010, issue of Clinical Infectious Diseases.
View SourceMay 28, 2010Provides Information
Microbicide Containing Engineered Bacteria May Inhibit HIV-1
Researchers from the U.S. and abroad used bacteria inherent to the human vaginal tract to develop a live, topical microbicide that may induce production of HIV-1 protein inhibitors and ultimately prevent transmission of the virus.
View SourceJuly 24, 2010Provides Information
Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV.
View SourceMay 7, 2010Provides Information
Most gay men in Asia-Pacific region 'denied HIV care'
Some 90% of gay men in the Asia-Pacific region are denied access to HIV/Aids help because of discriminatory laws in many states, a UN-backed report says.
View SourceMay 17, 2010Provides Information
N
NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing
NanoViricides, Inc. (the "Company"), announced that it has signed a Research Agreement with the University of California, San Francisco (UCSF) for testing of its anti-HIV drug candidates.
View SourceMay 18, 2010Provides Information
New HIV infections increasing among homosexuals
New HIV infections are increasing among homosexuals, drug users and prostitutes who don't seek help because of laws that criminalize these practices, the head of the U.N. AIDS agency said Monday.
View SourceMarch 16, 2010Provides Information
New HIV model suggests killer T cell for vaccine
Limited success in modelling the behaviour of the complex, unusual and unpredictable HIV virus has slowed efforts to develop an effective vaccine to prevent AIDS.
View SourceApril 29, 2010Provides Information
New HIV treatment guidelines indicate importance of early, individualized antiretroviral treatment
Advances in antiretroviral treatment (ART) have shown that the progressive immune system destruction caused by HIV infection, including AIDS, can be prevented, indicating the importance of beginning ART early, when a person with HIV infection is without symptoms, according to the 2010 recommendations of the International AIDS Society-USA Panel, published in the July 21 issue of JAMA, a theme issue on HIV/AIDS. This shift to earlier therapy is made possible by the increased understanding of the negative consequences of ongoing HIV replication and the development of newer drugs providing the potential for potent viral suppression in initial and subsequent therapy.
View SourceJuly 18, 2010Provides Information
New hope for HIV vaccine efforts
US researchers say they are a step closer to understanding why some people have natural protection against HIV.
View SourceMay 5, 2010Provides Information
New models predict short-term survival of HIV patients starting antiretroviral therapy in sub-saharan Africa
The survival of HIV patients in sub-Saharan Africa in the first year of antiretroviral therapy (ART) can now be predicted using either of two new risk models, developed by Matthias Egger from the University of Bern in Switzerland and Dr Margaret May, University of Bristol, UK, and international colleagues, and published in an Article Online First and in this week's edition of The Lancet.
View SourceJuly 15, 2010Provides Information
Novel microfluidic HIV test is quick and cheap
UC Davis biomedical engineer Prof. Alexander Revzin has developed a "lab on a chip" device for HIV testing. Revzin's microfluidic device uses antibodies to "capture" white blood cells called T cells that are affected by HIV. In addition to physically binding these cells the test detects the types and levels of inflammatory proteins (cytokines) released by the cells.
View SourceJuly 16, 2010Provides Information
Novel Strategy for Generating Induced Pluripotent Stem Cells for Clinical Use Is Safe and Efficient, Study Finds
A new technique for reprogramming human adult cells could greatly improve the safety and efficiency of producing patient-specific stem cells for use in a range of therapeutic applications to repair or replace damaged or diseased tissues, according to new research.
View SourceApril 19, 2010Provides Information
O
Obama administration prepares to announce first national HIV strategy
Kaiser Health News: "Federal officials plan to announce Tuesday a national strategy designed to ramp up and better coordinate the government's attack on the country's HIV/AIDS epidemic."
View SourceJuly 12, 2010Provides Information
Obama HIV/AIDS plan calls for reducing infections
President Barack Obama is announcing a new national strategy for combatting HIV and AIDS aimed at helping reduce the number of infections and providing those living with the virus high-quality care free from stigma or discrimination.
View SourceJuly 13, 2010Provides Information
Obama pledges to up AIDS fight
Despite economic hard times, president says will redouble efforts
View SourceJuly 23, 2010Provides Information
Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study
Study underscores need to expand programs striving for global pediatric AIDS control
View SourceJuly 20, 2010Provides Information
P
PARC Develops iPod-Sized HIV-Detection Device to Bring Affordable Testing To Rural Communities
The monetary and energy expense of HIV testing machines prevent their deployment to remote or impoverished areas; the very places that need them the most. To rectify that inequity, Palo Alto Research Center (PARC) has created a battery-operated HIV testing device the size of an iPod. The machine can return a test result in 10 minutes, and costs significantly less than the large machines used in most hospitals.
View SourceApril 2, 2010Provides Information
Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria.
View SourceJuly 19, 2010Provides Information
Potential HIV drug keeps virus out of cells
Following up a pioneering 2007 proof-of-concept study, a University of Utah biochemist and colleagues have developed a promising new anti-HIV drug candidate, PIE12-trimer, that prevents HIV from attacking human cells.
View SourceAugust 18, 2010Provides Information
Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ZFN approach enables the permanent disruption of the CCR5 gene, which encodes an important receptor for HIV infection, in all the cell types comprising the immune system that develop from hematopoietic stem cells (HSCs), and is the basis for a promising therapeutic strategy for the treatment of HIV/AIDS. Sangamo has two ongoing Phase 1 clinical trials to evaluate the safety and clinical efficacy of this approach in CD4+ T-cells.
View SourceJuly 6, 2010Provides Information
Prostitution Probably Not Source of HIV Epidemics
Swedish researchers have been inconspicuously monitoring the Brazilian sex industry, trying to understand the patterns of interaction between prostitutes and their clients. Using this data they analyzed how HIV would spread within the sex industry and whether it could be a source of an epidemic. Quite surprisingly, the researchers claim that prostitution, at least of the variety studied in Brazil, does not seem to have the pattern necessary to lead to an epidemic.
View SourceJune 21, 2010Provides Information
R
Research and Markets offers report on global markets for HIV drugs
Research and Markets has announced the addition of the "HIV Drugs - Global Strategic Business Report" report to their offering.
View SourceMay 25, 2010Provides Information
Researchers Identify Two FDA Approved Drugs That May Fight HIV
Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.
View SourceAugust 20, 2010Provides Information
Researchers Zero in on Protein that Destroys HIV
Using a $225,000 microscope, researchers have identified the key components of a protein called TRIM5a that destroys HIV in rhesus monkeys.
View SourceAugust 20, 2010Provides Information
Routine emergency dept. HIV screenings find only small increase in newly diagnosed HIV patients
The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.
View SourceJuly 18, 2010Provides Information
S
Stem-cell work closes a door to AIDS virus
Lab work on mice has opened up a novel way of closing a gateway to the AIDS virus, according to a study published on Friday.
View SourceJuly 2, 2010Provides Information
Strong new vaginal gels may block HIV
Dissolvable strips, drug-infused rings are latest efforts
View SourceMay 17, 2010Provides Information
Structure of Key HIV Protein Revealed
Researchers at Caltech have uncovered the structure of clade C gp120 - an HIV surface glycoprotein that interacts with CD4 receptors and is essential for viral entry into cells. HIV-1 clade C is the most rapidly spreading subtype of HIV, infecting millions of people primarily in Africa and Asia.
View SourceApril 5, 2010Provides Information
Study finds early HAART during TB treatment boosts survival rate in co-infected people
A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard. This finding by scientists co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the French National Agency for Research on AIDS and Viral Hepatitis, brings physicians closer to optimizing the treatment of severely immunosuppressed individuals with HIV-TB co-infection.
View SourceJuly 22, 2010Provides Information
Study reveals state of HIV/AIDS in Middle East, North Africa
A new study led by Weill Cornell Medical College in Qatar researcher Laith Abu-Raddad was the foundation for a report on HIV/AIDS in the Middle East and North Africa presented June 28 in Dubai.
View SourceJuly 9, 2010Provides Information
T
TB prevalence more common among HIV patients and aged individuals
A study by the Barcelona Public Health Agency has revealed those sections of the population that are most vulnerable to tuberculosis. The research, published in the journal Respiratory Research, shows that the highest death rates from this disease are among those aged over 50 or infected with HIV.
View SourceMarch 24, 2010Provides Information
U
UN expert: AIDS crisis in the world's prisons
The U.N.'s top investigator on torture and punishment warned Friday that overcrowded prisons are breeding grounds for AIDS.
View SourceJuly 23, 2010Provides Information
UN Says Mother-Child HIV Can Be Eliminated by 2015
The United Nations says mother-to-child HIV transmission can be eliminated by 2015 if health programs receive increased investments as planned.
View SourceMarch 8, 2010Provides Information
Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
Implementing a program of universal HIV testing and immediate antiretroviral treatment (ART) for infected individuals could have a major impact on the HIV/AIDS epidemic in Washington, DC, but a new study finds that it would not halt the epidemic, something that a previous report had projected. In a paper that will appear in the August 15 issue of Clinical Infectious Diseases and has been released online, researchers find that the so-called "test-and-treat" strategy could reduce new HIV infections by 15 percent over the next five years while conferring large survival benefits to HIV-infected patients.
View SourceJuly 9, 2010Provides Information
Using Antiretroviral to Prevent HIV Could Result in Drug Resistance If Routine Screening Is Not Done, Study Finds
Their scientific methods may have been quite different, but their conclusions were not. In asking whether drug resistance could be a problem if antiretroviral (ARV) drugs become a mainstay for HIV prevention, two studies -- one involving a mathematical model and the other assays of cells and tissue -- arrived at the same answer. Resistance could happen if people who are unknowingly already infected use the approach.
View SourceMay 25, 2010Provides Information
Y
Yorkshire hospital patients face tests in HIV scare
More than 500 hospital patients in Yorkshire are being offered HIV tests after it emerged a healthcare worker who treated them had the virus.
View SourceJune 22, 2010Provides Information
Youth Put a Dent in AIDS Epidemic
United Nations Study Shows Behavioral Changes Among Young People May Help Improve AIDS Outlook
View SourceJuly 13, 2010Provides Information
Z
Zambia court awards damages in HIV screening test case
Two ex-officers in Zambia's air force have been awarded damages following claims they were tested and treated for HIV without their knowledge.
View SourceMay 27, 2010Provides Information
© 1997 - 2010 The MerchantStore